Cover Image
市場調查報告書

化療誘發性噁心和嘔吐(CINV) - 開發中產品分析

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 245963
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性噁心和嘔吐(CINV) - 開發中產品分析 Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 98 Pages
簡介

化療誘發性噁心和嘔吐(CINV)是化療所引起的心律上升、發汗、暈眩、唾液增加等噁心嘔吐的症狀,發病要素一般認為是年齡、藥物、給藥、給藥行程及給藥途徑等。

本報告提供化療誘發性噁心和嘔吐(CINV)之治療藥開發情形調查分析,提供您開發中產品概要、臨床實驗的各階段產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

化療誘發性噁心和嘔吐(CINV)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

治療藥的開發企業

  • Kyowa Hakko Kirin
  • BioDelivery Sciences International, Inc.
  • Heron Therapeutics, Inc.
  • Suda Ltd
  • Aphios Corporation
  • Genovate Biotechnology Co., LTD.
  • Teikoku Pharma USA, Inc.
  • SymBio Pharmaceuticals Limited
  • INSYS Therapeutics, Inc.
  • Helsinn Healthcare S.A.
  • 新日本化學
  • Acacia Pharma Ltd.
  • Helsinn Holding S.A.
  • RedHill Biopharma Ltd.
  • Tesaro, Inc.

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • granisetron - Drug Profile
  • palonosetron hydrochloride - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • rolapitant hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • ondansetron hydrochloride CR - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • dronabinol - Drug Profile
  • rolapitant hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • APD-403 - Drug Profile
  • granisetron - Drug Profile
  • APD-421 - Drug Profile
  • ondansetron hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • dronabinol - Drug Profile
  • TPW-146 - Drug Profile
  • ondansetron hydrochloride - Drug Profile
  • granisetron - Drug Profile

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9572IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 2, 6, 3, 1, 11, 3 and 3 respectively.

Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Chemotherapy Induced Nausea and Vomiting - Overview 6
  • Chemotherapy Induced Nausea and Vomiting - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Products under Development by Companies 11
  • Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment 13
  • Assessment by Target 13
  • Assessment by Mechanism of Action 15
  • Assessment by Route of Administration 17
  • Assessment by Molecule Type 19
  • Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development 20
  • Acacia Pharma Ltd 20
  • Aphios Corp 20
  • Astellas Pharma Inc 21
  • Athenex Inc 21
  • Camurus AB 22
  • Daewoong Pharmaceutical Co Ltd 22
  • Heron Therapeutics Inc 23
  • Insys Therapeutics Inc 23
  • Kyowa Hakko Kirin Co Ltd 24
  • MannKind Corp 24
  • Medlab Clinical Ltd 25
  • N4 Pharma Plc 25
  • Nanoform Cardiovascular Therapeutics Ltd 26
  • Nemus Bioscience Inc 26
  • RedHill Biopharma Ltd 27
  • Serina Therapeutics Inc 27
  • SoluBest Ltd 28
  • Suda Ltd 28
  • Tesaro Inc 29
  • Therapix Biosciences Ltd 29
  • Chemotherapy Induced Nausea and Vomiting - Drug Profiles 30
  • (netupitant + palonosetron hydrochloride) - Drug Profile 30
  • (palonosetron hydrochloride + Pro-netupitant) - Drug Profile 34
  • APD-403 - Drug Profile 35
  • aprepitant - Drug Profile 37
  • aprepitant - Drug Profile 38
  • aprepitant - Drug Profile 39
  • aprepitant - Drug Profile 40
  • aprepitant - Drug Profile 41
  • aprepitant - Drug Profile 42
  • Cannabis CINV - Drug Profile 43
  • dexamethasone - Drug Profile 44
  • dronabinol - Drug Profile 45
  • dronabinol - Drug Profile 46
  • FK-886 - Drug Profile 47
  • fosnetupitant - Drug Profile 49
  • granisetron hydrochloride - Drug Profile 50
  • granisetron hydrochloride - Drug Profile 51
  • granisetron hydrochloride - Drug Profile 52
  • granisetron hydrochloride ER - Drug Profile 53
  • LPI-1504 - Drug Profile 55
  • LPI-1505 - Drug Profile 56
  • NB-1222 - Drug Profile 57
  • NB-2111 - Drug Profile 58
  • netupitant - Drug Profile 59
  • ondansetron hydrochloride - Drug Profile 60
  • ondansetron hydrochloride - Drug Profile 62
  • ondansetron hydrochloride - Drug Profile 63
  • ondansetron hydrochloride - Drug Profile 64
  • ondansetron hydrochloride CR - Drug Profile 65
  • palmidrol - Drug Profile 72
  • palonosetron hydrochloride - Drug Profile 73
  • rolapitant hydrochloride - Drug Profile 74
  • SER-232 - Drug Profile 80
  • Zindol - Drug Profile 81
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects 82
  • Chemotherapy Induced Nausea and Vomiting - Discontinued Products 83
  • Chemotherapy Induced Nausea and Vomiting - Product Development Milestones 84
  • Featured News & Press Releases 84
  • Appendix 94
  • Methodology 94
  • Coverage 94
  • Secondary Research 94
  • Primary Research 94
  • Expert Panel Validation 94
  • Contact Us 94
  • Disclaimer 95

List of Tables

  • Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex Inc, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics Inc, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Insys Therapeutics Inc, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Medlab Clinical Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by N4 Pharma Plc, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience Inc, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro Inc, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Therapix Biosciences Ltd, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2017
  • Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top